Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).
The global market for Familial Amyloid Polyneuropathy Therapeutic is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Familial Amyloid Polyneuropathy Therapeutic market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Familial Amyloid Polyneuropathy Therapeutic market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Familial Amyloid Polyneuropathy Therapeutic market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Familial Amyloid Polyneuropathy Therapeutic market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Familial Amyloid Polyneuropathy Therapeutic players cover Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc. and Proclara Biosciences and etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Familial Amyloid Polyneuropathy Therapeutic market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Familial Amyloid Polyneuropathy Therapeutic market, with both quantitative and qualitative data, to help readers understand how the Familial Amyloid Polyneuropathy Therapeutic market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Familial Amyloid Polyneuropathy Therapeutic market and forecasts the market size by Drug Type (Inotersen, Tafamidis and Patisiran), by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by drug type
Inotersen
Tafamidis
Patisiran
Others
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Pfizer Inc.
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Corino Therapeutics Inc.
Proclara Biosciences
Arcturus Therapeutics Inc
Chapter Introduction
Chapter 1: Scope of Familial Amyloid Polyneuropathy Therapeutic, Research Methodology, etc.
Chapter 2: Executive Summary, global Familial Amyloid Polyneuropathy Therapeutic market size and CAGR, Familial Amyloid Polyneuropathy Therapeutic market size by region, by drug type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Familial Amyloid Polyneuropathy Therapeutic revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Familial Amyloid Polyneuropathy Therapeutic revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by drug type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Familial Amyloid Polyneuropathy Therapeutic market size forecast by region, by country, by drug type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences and Arcturus Therapeutics Inc, etc.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size 2017-2028
2.1.2 Familial Amyloid Polyneuropathy Therapeutic Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Familial Amyloid Polyneuropathy Therapeutic Segment by Drug Type
2.2.1 Inotersen
2.2.2 Tafamidis
2.2.3 Patisiran
2.2.4 Others
2.3 Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type
2.3.1 Familial Amyloid Polyneuropathy Therapeutic Market Size CAGR by Drug Type (2017 VS 2022 VS 2028)
2.3.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type (2017-2022)
2.4 Familial Amyloid Polyneuropathy Therapeutic Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.4.4 Others
2.5 Familial Amyloid Polyneuropathy Therapeutic Market Size by Application
2.5.1 Familial Amyloid Polyneuropathy Therapeutic Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application (2017-2022)
3 Familial Amyloid Polyneuropathy Therapeutic Market Size by Player
3.1 Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Players
3.1.1 Global Familial Amyloid Polyneuropathy Therapeutic Revenue by Players (2020-2022)
3.1.2 Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Players (2020-2022)
3.2 Global Familial Amyloid Polyneuropathy Therapeutic Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Familial Amyloid Polyneuropathy Therapeutic by Regions
4.1 Familial Amyloid Polyneuropathy Therapeutic Market Size by Regions (2017-2022)
4.2 Americas Familial Amyloid Polyneuropathy Therapeutic Market Size Growth (2017-2022)
4.3 APAC Familial Amyloid Polyneuropathy Therapeutic Market Size Growth (2017-2022)
4.4 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Growth (2017-2022)
4.5 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Growth (2017-2022)
5 Americas
5.1 Americas Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022)
5.2 Americas Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022)
5.3 Americas Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2017-2022)
6.2 APAC Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022)
6.3 APAC Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Familial Amyloid Polyneuropathy Therapeutic by Country (2017-2022)
7.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022)
7.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic by Region (2017-2022)
8.2 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022)
8.3 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.1 Global Familial Amyloid Polyneuropathy Therapeutic Forecast by Regions (2023-2028)
10.1.1 Global Familial Amyloid Polyneuropathy Therapeutic Forecast by Regions (2023-2028)
10.1.2 Americas Familial Amyloid Polyneuropathy Therapeutic Forecast
10.1.3 APAC Familial Amyloid Polyneuropathy Therapeutic Forecast
10.1.4 Europe Familial Amyloid Polyneuropathy Therapeutic Forecast
10.1.5 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Forecast
10.2 Americas Familial Amyloid Polyneuropathy Therapeutic Forecast by Country (2023-2028)
10.2.1 United States Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.2.2 Canada Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.2.3 Mexico Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.2.4 Brazil Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.3 APAC Familial Amyloid Polyneuropathy Therapeutic Forecast by Region (2023-2028)
10.3.1 China Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.3.2 Japan Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.3.3 Korea Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.3.4 Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.3.5 India Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.3.6 Australia Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.4 Europe Familial Amyloid Polyneuropathy Therapeutic Forecast by Country (2023-2028)
10.4.1 Germany Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.4.2 France Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.4.3 UK Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.4.4 Italy Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.4.5 Russia Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.5 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Forecast by Region (2023-2028)
10.5.1 Egypt Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.5.2 South Africa Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.5.3 Israel Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.5.4 Turkey Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.5.5 GCC Countries Familial Amyloid Polyneuropathy Therapeutic Market Forecast
10.6 Global Familial Amyloid Polyneuropathy Therapeutic Forecast by Drug Type (2023-2028)
10.7 Global Familial Amyloid Polyneuropathy Therapeutic Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Information
11.1.2 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product Offered
11.1.3 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Pfizer Inc. Main Business Overview
11.1.5 Pfizer Inc. Latest Developments
11.2 Alnylam Pharmaceuticals Inc.
11.2.1 Alnylam Pharmaceuticals Inc. Company Information
11.2.2 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product Offered
11.2.3 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Alnylam Pharmaceuticals Inc. Main Business Overview
11.2.5 Alnylam Pharmaceuticals Inc. Latest Developments
11.3 Ionis Pharmaceuticals Inc.
11.3.1 Ionis Pharmaceuticals Inc. Company Information
11.3.2 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product Offered
11.3.3 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Ionis Pharmaceuticals Inc. Main Business Overview
11.3.5 Ionis Pharmaceuticals Inc. Latest Developments
11.4 Corino Therapeutics Inc.
11.4.1 Corino Therapeutics Inc. Company Information
11.4.2 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product Offered
11.4.3 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Corino Therapeutics Inc. Main Business Overview
11.4.5 Corino Therapeutics Inc. Latest Developments
11.5 Proclara Biosciences
11.5.1 Proclara Biosciences Company Information
11.5.2 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product Offered
11.5.3 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Proclara Biosciences Main Business Overview
11.5.5 Proclara Biosciences Latest Developments
11.6 Arcturus Therapeutics Inc
11.6.1 Arcturus Therapeutics Inc Company Information
11.6.2 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product Offered
11.6.3 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2022)
11.6.4 Arcturus Therapeutics Inc Main Business Overview
11.6.5 Arcturus Therapeutics Inc Latest Developments
12 Research Findings and Conclusion
List of Tables
Table 1. Familial Amyloid Polyneuropathy Therapeutic Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Inotersen
Table 3. Major Players of Tafamidis
Table 4. Major Players of Patisiran
Table 5. Major Players of Others
Table 6. Familial Amyloid Polyneuropathy Therapeutic Market Size CAGR by Drug Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 7. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & ($ Millions)
Table 8. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type (2017-2022)
Table 9. Familial Amyloid Polyneuropathy Therapeutic Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 10. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & ($ Millions)
Table 11. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application (2017-2022)
Table 12. Global Familial Amyloid Polyneuropathy Therapeutic Revenue by Players (2020-2022) & ($ Millions)
Table 13. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Player (2020-2022)
Table 14. Familial Amyloid Polyneuropathy Therapeutic Key Players Head office and Products Offered
Table 15. Familial Amyloid Polyneuropathy Therapeutic Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Regions 2017-2022 & ($ Millions)
Table 19. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Regions (2017-2022)
Table 20. Americas Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022) & ($ Millions)
Table 21. Americas Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Country (2017-2022)
Table 22. Americas Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & ($ Millions)
Table 23. Americas Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type (2017-2022)
Table 24. Americas Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & ($ Millions)
Table 25. Americas Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application (2017-2022)
Table 26. APAC Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2017-2022) & ($ Millions)
Table 27. APAC Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Region (2017-2022)
Table 28. APAC Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & ($ Millions)
Table 29. APAC Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type (2017-2022)
Table 30. APAC Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & ($ Millions)
Table 31. APAC Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application (2017-2022)
Table 32. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022) & ($ Millions)
Table 33. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Country (2017-2022)
Table 34. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & ($ Millions)
Table 35. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type (2017-2022)
Table 36. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & ($ Millions)
Table 37. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application (2017-2022)
Table 38. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2017-2022) & ($ Millions)
Table 39. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Region (2017-2022)
Table 40. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & ($ Millions)
Table 41. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type (2017-2022)
Table 42. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & ($ Millions)
Table 43. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application (2017-2022)
Table 44. Key Market Drivers & Growth Opportunities of Familial Amyloid Polyneuropathy Therapeutic
Table 45. Key Market Challenges & Risks of Familial Amyloid Polyneuropathy Therapeutic
Table 46. Key Industry Trends of Familial Amyloid Polyneuropathy Therapeutic
Table 47. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 48. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share Forecast by Regions (2023-2028)
Table 49. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Drug Type (2023-2028) & ($ Millions)
Table 50. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share Forecast by Drug Type (2023-2028)
Table 51. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 52. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share Forecast by Application (2023-2028)
Table 53. Pfizer Inc. Details, Company Type, Familial Amyloid Polyneuropathy Therapeutic Area Served and Its Competitors
Table 54. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product Offered
Table 55. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 56. Pfizer Inc. Main Business
Table 57. Pfizer Inc. Latest Developments
Table 58. Alnylam Pharmaceuticals Inc. Details, Company Type, Familial Amyloid Polyneuropathy Therapeutic Area Served and Its Competitors
Table 59. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product Offered
Table 60. Alnylam Pharmaceuticals Inc. Main Business
Table 61. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 62. Alnylam Pharmaceuticals Inc. Latest Developments
Table 63. Ionis Pharmaceuticals Inc. Details, Company Type, Familial Amyloid Polyneuropathy Therapeutic Area Served and Its Competitors
Table 64. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product Offered
Table 65. Ionis Pharmaceuticals Inc. Main Business
Table 66. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 67. Ionis Pharmaceuticals Inc. Latest Developments
Table 68. Corino Therapeutics Inc. Details, Company Type, Familial Amyloid Polyneuropathy Therapeutic Area Served and Its Competitors
Table 69. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product Offered
Table 70. Corino Therapeutics Inc. Main Business
Table 71. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 72. Corino Therapeutics Inc. Latest Developments
Table 73. Proclara Biosciences Details, Company Type, Familial Amyloid Polyneuropathy Therapeutic Area Served and Its Competitors
Table 74. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product Offered
Table 75. Proclara Biosciences Main Business
Table 76. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 77. Proclara Biosciences Latest Developments
Table 78. Arcturus Therapeutics Inc Details, Company Type, Familial Amyloid Polyneuropathy Therapeutic Area Served and Its Competitors
Table 79. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product Offered
Table 80. Arcturus Therapeutics Inc Main Business
Table 81. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 82. Arcturus Therapeutics Inc Latest Developments
List of Figures
List of Figures
Figure 1. Familial Amyloid Polyneuropathy Therapeutic Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type in 2021
Figure 7. Familial Amyloid Polyneuropathy Therapeutic in Hospital Pharmacies
Figure 8. Global Familial Amyloid Polyneuropathy Therapeutic Market: Hospital Pharmacies (2017-2022) & ($ Millions)
Figure 9. Familial Amyloid Polyneuropathy Therapeutic in Retail Pharmacies
Figure 10. Global Familial Amyloid Polyneuropathy Therapeutic Market: Retail Pharmacies (2017-2022) & ($ Millions)
Figure 11. Familial Amyloid Polyneuropathy Therapeutic in Online Pharmacies
Figure 12. Global Familial Amyloid Polyneuropathy Therapeutic Market: Online Pharmacies (2017-2022) & ($ Millions)
Figure 13. Familial Amyloid Polyneuropathy Therapeutic in Others
Figure 14. Global Familial Amyloid Polyneuropathy Therapeutic Market: Others (2017-2022) & ($ Millions)
Figure 15. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application in 2021
Figure 16. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Player in 2021
Figure 17. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Regions (2017-2022)
Figure 18. Americas Familial Amyloid Polyneuropathy Therapeutic Market Size 2017-2022 ($ Millions)
Figure 19. APAC Familial Amyloid Polyneuropathy Therapeutic Market Size 2017-2022 ($ Millions)
Figure 20. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size 2017-2022 ($ Millions)
Figure 21. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size 2017-2022 ($ Millions)
Figure 22. Americas Familial Amyloid Polyneuropathy Therapeutic Value Market Share by Country in 2021
Figure 23. Americas Familial Amyloid Polyneuropathy Therapeutic Consumption Market Share by Drug Type in 2021
Figure 24. Americas Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application in 2021
Figure 25. United States Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 26. Canada Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 27. Mexico Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 28. Brazil Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 29. APAC Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Region in 2021
Figure 30. APAC Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application in 2021
Figure 31. China Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 32. Japan Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 33. Korea Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 34. Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 35. India Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 36. Australia Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 37. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Country in 2021
Figure 38. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type in 2021
Figure 39. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application in 2021
Figure 40. Germany Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 41. France Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 42. UK Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 43. Italy Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 44. Russia Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 45. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Region in 2021
Figure 46. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type in 2021
Figure 47. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application in 2021
Figure 48. Egypt Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 49. South Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 50. Israel Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 51. Turkey Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 52. GCC Country Familial Amyloid Polyneuropathy Therapeutic Market Size Growth 2017-2022 ($ Millions)
Figure 53. Americas Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 54. APAC Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 55. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 56. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 57. United States Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 58. Canada Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 59. Mexico Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 60. Brazil Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 61. China Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 62. Japan Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 63. Korea Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 64. Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 65. India Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 66. Australia Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 67. Germany Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 68. France Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 69. UK Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 70. Italy Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 71. Russia Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 72. Spain Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 73. Egypt Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 74. South Africa Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 75. Israel Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 76. Turkey Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)
Figure 77. GCC Countries Familial Amyloid Polyneuropathy Therapeutic Market Size 2023-2028 ($ Millions)